Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors : Current Opinion in Oncology

Secondary Logo

Journal Logo

HEMATOLOGIC MALIGNANCIES: Edited by Miguel A. Sanz and María-Victoria Mateos

Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors

Breccia, Massimo; Assanto, Giovanni Manfredi; Laganà, Alessandro; Scalzulli, Emilia; Martelli, Maurizio

Author Information
Current Opinion in Oncology 34(6):p 729-737, November 2022. | DOI: 10.1097/CCO.0000000000000898

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid